Schubert & CO Prothena Corp Public LTD CO Transaction History

Schubert & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	BUY	$46.97 - $58.27 $46 - $58	1 Added 7.69%	14 $0
Q4 2022 Jan 31, 2023	BUY	$52.05 - $65.0 $156 - $195	3 Added 30.0%	13 $0
Q3 2022 Oct 21, 2022	BUY	$25.16 - $60.63 $100 - $242	4 Added 66.67%	10 $1,000
Q2 2022 Aug 01, 2022	BUY	$22.73 - $39.98 $68 - $119	3 Added 100.0%	6 $0
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $90 - $147	3 New	3 $0

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.